Bausch Health Companies Inc. Reports Q1 2026 Results: Key Financial Highlights and Investor Insights

Overview

Bausch Health Companies Inc. (“BHC”, NYSE: BHC, TSX: BHC) has released its Form 10-Q for the quarter ended March 31, 2026, offering investors a detailed look at its financial and operational performance. The company, headquartered in Quebec, operates in the pharmaceutical preparations sector and remains a large accelerated filer, not an emerging growth or shell company.

Key Financial Highlights

• Common Shares Outstanding: 373,475,644 shares as of April 24, 2026.
• Cash and Cash Equivalents: \$1,299 million as of March 31, 2026, slightly down from \$1,309 million at year-end 2025.
• Total Assets: \$24,498 million at the end of Q1 2026, compared to \$26,366 million at December 31, 2025.
• Total Liabilities: \$25,580 million at March 31, 2026, down from \$25,989 million at year-end 2025.
• Current Assets: \$6,157 million (Q1 2026), a decrease from \$6,562 million (year-end 2025).
• Key Non-Current Assets: Goodwill (\$11,271 million), Deferred Tax Assets (\$1,845 million), Other Non-Current Assets (\$369 million).
• Current Liabilities: Accounts Payable (\$593 million), Accrued Liabilities (\$3,283 million), Current Portion of Long-Term Debt (\$889 million), Financial Leases (\$11 million).
• Non-Current Liabilities: Secured Borrowing (\$20 million), Deferred Income Tax Liabilities (\$146 million), Other Non-Current Liabilities (\$763 million).
• Shareholders’ (Deficit) Equity: The company continues to reflect a deficit in equity, with common shares issued and outstanding at 373,464,760 (Q1 2026) and 370,531,987 (year-end 2025). The value of common shares stands at \$10,542 million.

Operational and Strategic Updates

• Reportable Segments: Five reportable and operating segments, reflecting a diversified business structure.
• Planned Separation of Eye Health Business: Bausch Health continues with the planned separation of its global eye health business (Bausch + Lomb), including Vision Care, Surgical, and Pharmaceuticals. This separation is expected to be a significant strategic move, with anticipated terms, timing, and costs outlined. Investors should monitor for further updates, as this could materially impact BHC’s valuation and operational focus.
• Forward-Looking Statements: Management highlights several potential risks and opportunities, notably:
  • Execution of business strategy, operational efficiency initiatives, and pipeline commercialization.
  • Competitive positioning and pricing for both current and anticipated products.
  • Successful development, regulatory approval, and launch of new products.
  • Integration and expected benefits from acquisitions and strategic transactions.
  • Impact of macroeconomic and geopolitical factors, including inflation, recessionary pressures, currency fluctuations, and tax law changes.
  • The effect of the Inflation Reduction Act (IRA) and CMS selection of Xifaxan for potential price negotiation, which could significantly impact revenues if pricing is affected.
  • Ongoing legal proceedings, contingencies, and product quality matters.
• Regulatory and Legal Matters: The company references ongoing litigation and contingencies, with specific mention of Canadian securities litigation. Shareholders should remain alert to potential outcomes, as these could materially affect the share price.
• Commitments and Contingencies: Noted in the report, but details deferred to Note 17. Investors should review this note for any material liabilities or risks.

Potential Price-Sensitive Issues

• Separation of Bausch + Lomb: The planned spin-off could be a major catalyst, impacting both operational focus and share valuation. Investors should monitor timing and terms closely.
• Xifaxan Price Negotiations: The selection of Xifaxan by CMS for IRA-related price negotiations could negatively affect revenues from this key product, which would be material for BHC’s financials.
• Legal and Regulatory Risks: Uncertainties related to ongoing litigation and regulatory changes (including tax law changes and product exclusivity) could have significant effects on BHC’s results and share price.
• Balance Sheet Deficit: The company continues to carry a deficit in shareholder equity, which may concern some investors regarding financial stability.
• Declining Asset Base: The decrease in total assets from year-end 2025 to Q1 2026 may reflect asset sales, write-downs, or other strategic moves; investors should seek clarification in the management discussion.

Conclusion

Bausch Health Companies Inc.’s Q1 2026 report reveals a company in transition, with significant strategic moves underway, particularly the separation of its eye health business. The company’s balance sheet remains highly leveraged, with a deficit in equity and substantial liabilities. Risks remain around regulatory and legal issues, particularly with key products facing potential pricing pressure. Investors should closely monitor developments regarding the Bausch + Lomb separation and Xifaxan pricing, as these are likely to be share price movers in the coming quarters.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The information herein is based on Bausch Health Companies Inc.’s Form 10-Q for Q1 2026 and is subject to change. The author does not accept any liability for decisions made based on this article.

View Bausch Health Companies Inc. Historical chart here